Regulus Therapeutics (RGLS) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. SPY

Go back to Regulus Therapeutics (RGLS) Misses Q2 EPS by 8c

Regulus Reports Second Quarter 2017 Financial Results and Recent Events

August 1, 2017 4:10 PM EDT

LA JOLLA, Calif., Aug. 1, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the six months ended June 30, 2017 and recent events.  

"The successful completion of our recent public offering significantly strengthens our financial position through key clinical milestones of our lead programs, RG-012 and RGLS4326,"... More